201 related articles for article (PubMed ID: 25120800)
1. Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm.
Yang QC; Wang YH; Lin Y; Xue L; Chen YJ; Chen MH; Chen J
Int J Clin Exp Pathol; 2014; 7(7):4204-12. PubMed ID: 25120800
[TBL] [Abstract][Full Text] [Related]
2. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
[TBL] [Abstract][Full Text] [Related]
3. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
4. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
5. The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: a clinicopathologic and immunohistochemical study of 12 cases at a single institution.
Chang IW; Lin JW; Wu YT
J Neurooncol; 2011 Dec; 105(3):563-72. PubMed ID: 21667225
[TBL] [Abstract][Full Text] [Related]
6. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET).
Viúdez A; Carvalho FL; Maleki Z; Zahurak M; Laheru D; Stark A; Azad NS; Wolfgang CL; Baylin S; Herman JG; De Jesus-Acosta A
Oncotarget; 2016 May; 7(18):24950-61. PubMed ID: 26894863
[TBL] [Abstract][Full Text] [Related]
7. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
8. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma.
Isohookana J; Haapasaari KM; Soini Y; Leppänen J; Karihtala P
Pathol Res Pract; 2018 Jun; 214(6):840-847. PubMed ID: 29735403
[TBL] [Abstract][Full Text] [Related]
9. O
Watanabe H; Yamazaki Y; Fujishima F; Izumi K; Imamura M; Hijioka S; Toriyama K; Yatabe Y; Kudo A; Motoi F; Unno M; Sasano H
BMC Cancer; 2020 Dec; 20(1):1195. PubMed ID: 33287738
[TBL] [Abstract][Full Text] [Related]
10. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Spiegl-Kreinecker S; Pirker C; Filipits M; Lötsch D; Buchroithner J; Pichler J; Silye R; Weis S; Micksche M; Fischer J; Berger W
Neuro Oncol; 2010 Jan; 12(1):28-36. PubMed ID: 20150365
[TBL] [Abstract][Full Text] [Related]
11. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expression.
Rahman WF; Rahman KS; Nafi SN; Fauzi MH; Jaafar H
Int J Clin Exp Pathol; 2015; 8(6):6095-106. PubMed ID: 26261487
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A
Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592
[TBL] [Abstract][Full Text] [Related]
15. MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis.
Sawhney M; Rohatgi N; Kaur J; Gupta SD; Deo SV; Shukla NK; Ralhan R
Oral Oncol; 2007 May; 43(5):515-22. PubMed ID: 16996781
[TBL] [Abstract][Full Text] [Related]
16. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma.
Zhang JF; Chen Y; Lin GS; Zhang JD; Tang WL; Huang JH; Chen JS; Wang XF; Lin ZX
Hum Pathol; 2016 Jun; 52():136-44. PubMed ID: 26980050
[TBL] [Abstract][Full Text] [Related]
17. Application of AJCC/UICC and WHO-2010 classifications for GEP-NEN in Chinese patients.
Ye BX; Heng D; Jiang LQ; Wang Y; Zhang HJ; Lin L
J Dig Dis; 2015 May; 16(5):264-71. PubMed ID: 25707298
[TBL] [Abstract][Full Text] [Related]
18. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of MGMT expression on low-grade gangliogliomas: a clinicopathological and immunohistochemical study.
Chang IW; Hsu CT; Lin JW; Hung CH
Folia Neuropathol; 2013; 51(4):275-82. PubMed ID: 24374955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]